First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma : Results of the B-R-ENDA Trial
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association..
The incidence of aggressive B-cell lymphomas increases with age, but for elderly or frail patients not eligible for doxorubicin-containing treatment standard therapy remains to be defined. In this prospective, multicenter, phase-2 B-R-ENDA trial, we investigated the feasibility, toxicity, and efficacy of 8 cycles rituximab combined with 6 cycles bendamustine (BR) in elderly or frail aggressive B-cell lymphoma patients: 39 patients aged >80 years and 29 patients aged 61-80 years with elevated Cumulative Illness Rating Scalescore >6 were included. Progression-free survival (PFS) and overall survival (OS) at 2 years were 45% (95% confidence interval [CI], 28%-61%) and 46% (28%-63%) for the patients age >80, as well 32% (13%-51%) and 37% (17%-57%) for frail patients age 64-80, respectively. In a preplanned retrospective analysis, we found no significant differences in PFS and OS comparing the outcome of the 39 patients age >80 years with 40 patients aged 76-80 years treated with 6xR-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) and 2 x rituximab in the RICOVER-60 trial (DSHNHL 1999-1, NCT00052936, EU-20243), yet we detected lower rates of infections and treatment-related deaths in the BR-treated patients. We demonstrate that older and frail patients with aggressive B-cell lymphoma who are not able to receive standard CHOP-based therapy can benefit from anthracycline-free therapy as a feasible and effective therapeutic option.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
HemaSphere - 6(2022), 12 vom: 20. Dez., Seite e808 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Braulke, Friederike [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 10.12.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1097/HS9.0000000000000808 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349919283 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349919283 | ||
| 003 | DE-627 | ||
| 005 | 20231226043753.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/HS9.0000000000000808 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1166.xml |
| 035 | |a (DE-627)NLM349919283 | ||
| 035 | |a (NLM)36479544 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Braulke, Friederike |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma |b Results of the B-R-ENDA Trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.12.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. | ||
| 520 | |a The incidence of aggressive B-cell lymphomas increases with age, but for elderly or frail patients not eligible for doxorubicin-containing treatment standard therapy remains to be defined. In this prospective, multicenter, phase-2 B-R-ENDA trial, we investigated the feasibility, toxicity, and efficacy of 8 cycles rituximab combined with 6 cycles bendamustine (BR) in elderly or frail aggressive B-cell lymphoma patients: 39 patients aged >80 years and 29 patients aged 61-80 years with elevated Cumulative Illness Rating Scalescore >6 were included. Progression-free survival (PFS) and overall survival (OS) at 2 years were 45% (95% confidence interval [CI], 28%-61%) and 46% (28%-63%) for the patients age >80, as well 32% (13%-51%) and 37% (17%-57%) for frail patients age 64-80, respectively. In a preplanned retrospective analysis, we found no significant differences in PFS and OS comparing the outcome of the 39 patients age >80 years with 40 patients aged 76-80 years treated with 6xR-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) and 2 x rituximab in the RICOVER-60 trial (DSHNHL 1999-1, NCT00052936, EU-20243), yet we detected lower rates of infections and treatment-related deaths in the BR-treated patients. We demonstrate that older and frail patients with aggressive B-cell lymphoma who are not able to receive standard CHOP-based therapy can benefit from anthracycline-free therapy as a feasible and effective therapeutic option | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Zettl, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Ziepert, Marita |e verfasserin |4 aut | |
| 700 | 1 | |a Viardot, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Kahl, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Prange-Krex, Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Korfel, Agnieszka |e verfasserin |4 aut | |
| 700 | 1 | |a Dreyling, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Bott, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Wedding, Ulrich |e verfasserin |4 aut | |
| 700 | 1 | |a Reichert, Dietmar |e verfasserin |4 aut | |
| 700 | 1 | |a de Wit, Maike |e verfasserin |4 aut | |
| 700 | 1 | |a Hartmann, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Poeschel, Viola |e verfasserin |4 aut | |
| 700 | 1 | |a Schmitz, Norbert |e verfasserin |4 aut | |
| 700 | 1 | |a Witzens-Harig, Mathias |e verfasserin |4 aut | |
| 700 | 1 | |a Klapper, Wolfram |e verfasserin |4 aut | |
| 700 | 1 | |a Rosenwald, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Wulf, Gerald |e verfasserin |4 aut | |
| 700 | 1 | |a Altmann, Bettina |e verfasserin |4 aut | |
| 700 | 1 | |a Trümper, Lorenz |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t HemaSphere |d 2017 |g 6(2022), 12 vom: 20. Dez., Seite e808 |w (DE-627)NLM29509902X |x 2572-9241 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2022 |g number:12 |g day:20 |g month:12 |g pages:e808 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/HS9.0000000000000808 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2022 |e 12 |b 20 |c 12 |h e808 | ||